FDA’s Ganley “Disappointed” By Competitive Pain Reliever Marketing
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC head Charles Ganley, MD, chastised OTC pain reliever marketers for airing comparative DTC ads in the wake of COX-2 safety concerns during a speech May 6 at the Consumer Healthcare Products Association Regulatory & Scientific Conference in Washington, D.C
You may also be interested in...
FDA’s Rosebraugh Commends Ads Addressing Conscientious OTC Use
Drug marketers who communicate that their OTC products should be taken with the same care as prescription drugs are sending the right message, according to Curtis Rosebraugh, MD, deputy director of FDA's Office of Nonprescription Products
FDA’s Rosebraugh Commends Ads Addressing Conscientious OTC Use
Drug marketers who communicate that their OTC products should be taken with the same care as prescription drugs are sending the right message, according to Curtis Rosebraugh, MD, deputy director of FDA's Office of Nonprescription Products
Tylenol Ad Warns Of Undetected Aspirin Damage To Stomach
New marketing for McNeil's Tylenol highlights the potential for aspirin-related gastrointestinal injury that may go unnoticed by the consumer